Shanghai Fosun Pharmaceutical Group Co Ltd

Explore why Shanghai Fosun Pharmaceutical’s quiet market stance matters, the hidden pipeline insights, and how investors and partners can spot its next breakthrough in China’s innovation‑drug scene.

Shanghai Fosun Pharmaceutical Q4 2025 outlook: stable EPS, slight revenue dip, and a robust pipeline featuring a KRAS G12C oncology lead and a GLP‑1 diabetes candidate, all under strong cost‑control strategy.

Shanghai Fosun Pharma’s Q4 2025 outlook: steady EPS, a modest revenue lift, and a shift to high‑margin oncology drugs. Discover how the company plans to navigate pricing, patent cliffs, and M&A opportunities in China’s specialty‑drug market.

Fosun’s KAT6A/B inhibitor enters phase‑I trials, targeting solid tumours with a novel epigenetic mechanism and early safety data from China’s SDA approval.

Fosun Pharma’s new Jinan Fund stake transfer and drug registration approval signal strategic growth, boosting investor confidence in its innovation‑driven portfolio.

Shanghai Fosun Pharmaceutical’s new drug approval and Pfizer partnership put it in line for early market entry, patent‑cliff protection, and strong global revenue potential.

Fosun Pharma launches Phase‑I trials for FXS887, a novel oral agent targeting solid tumours, sparking investor interest and highlighting the rise of unique, cost‑effective anticancer drugs.

Shanghai Fosun Pharmaceutical Group Co Ltd has announced a strategic divestment of its stake in Shanghai Clon, a move aimed at sharpening its focus on core drug development and optimizing asset allocation in a dynamic healthcare market.

Shanghai Fosun Pharmaceutical Group Co Ltd is navigating a bearish market trend in the pharmaceutical sector, driven by macroeconomic uncertainties and geopolitical tensions, but its stable stock performance and robust market capitalization suggest …

The share price of Shanghai Fosun Pharmaceutical Group Co Ltd surged 3.2% to 42.30 CNY, driven by a combination of positive sector sentiment, strong company fundamentals, and supportive analyst commentary.